Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis

Experimental Eye Research

Volumn 86, Issue 5, 2008, Pages 791-797

  Sanchis Merino, M Eugenia ^a   Montero, Javier A ^a,b   Ruiz Moreno, Jose M ^b,c   Rodriguez, Alejandra E ^b   Pastor, Silvia ^b  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b Alicante   (Spain)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

allergic conjunctivitis; animal model; azelastine; benzalkonium chloride; emedastine; ketotifen; olopatadine; spaglumic acid

Indexed keywords

ALUMINUM HYDROXIDE; ANTIHISTAMINIC AGENT; AZELASTINE; BENZALKONIUM CHLORIDE; EMEDASTINE; EVANS BLUE; EYE DROPS; KETOTIFEN; OLOPATADINE; OVALBUMIN; SODIUM CHLORIDE; SPAGLUMIC ACID;

ALLERGIC CONJUNCTIVITIS; ALLERGIC REACTION; ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXTRAVASATION; EYE DISCHARGE; EYELID EDEMA; GUINEA PIG; MALE; NONHUMAN; OCULAR PRURITUS; OSMOLARITY; PH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SENSITIZATION; SPECTROPHOTOMETRY;

ANIMALS; ANTI-ALLERGIC AGENTS; BENZIMIDAZOLES; COLORING AGENTS; CONJUNCTIVITIS, ALLERGIC; DIBENZOXEPINS; DIPEPTIDES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EVANS BLUE; GUINEA PIGS; HISTAMINE H1 ANTAGONISTS; KETOTIFEN; MALE; OPHTHALMIC SOLUTIONS; PHTHALAZINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 42749094083     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2008.02.007     Document Type: Article

References (36)

1. Aguilar A.J. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol. Scand. 78 Suppl. 230 (2000) 52-55
2. Artal M.N., Luna J.D., and Discepola M. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%. Acta Ophthalmol. Scand. 78 Suppl. 230 (2000) 64-65
3. Austin J.B., Kaur B., Anderson H.R., Burr M., Harkins L.S., Strachan D.P., and Warner J.O. Hay fever, eczema, and wheeze: a nationwide UK study (ISAAC, international study of asthma and allergies in childhood). Arch. Dis. Child. 81 (1999) 225-230
4. Avunduk A.M., Tekelioglu Y., Turk A., and Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin. Ther. 27 (2005) 1392-1402
5. Bayer A., Uludag H.A., Sobaci G., and Mutlu F.M. Comparison of antiallergic drugs in an experimental model of ocular anaphylaxis. Ophthalmologica 217 (2003) 119-123
6. Bielory L. Differential diagnoses of conjunctivitis for clinical allergist-immunologists. Ann. Allergy Asthma Immunol. 98 (2007) 105-114 quiz 114-117, 152
7. Bonini S., Rasi G., Brusasco V., Carlsen K.H., Crimi E., Popov T., Schultze-Werninghaus G., Gramiccioni C., Bonini M., Passali D., Bachert C., van Cauwenberge P.B., Bresciani M., Bonini S., Calonge M., Montan P.G., Serapiao Dos Santos M., Belfort Jr. R., Lambiase A., and Sacchetti M. Nonspecific provocation of target organs in allergic diseases: EAACI-GA(2)LEN consensus report. Allergy 62 (2007) 683-694
8. Calonge M.C., Pastor J.C., Herreras J.M., and Gonzalez J.L. Pharmacologic modulation of vascular permeability in ocular allergy in the rat. Invest. Ophthalmol. Vis. Sci. 31 (1990) 176-180
9. Calonge M., Montero J.A., Herreras J.M., Ramon J.J., and Pastor J.C. Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy. Ann. Allergy Asthma Immunol. 77 (1996) 124-130
10. Calonge M., Siemasko K.F., and Stern M.E. Animal models of ocular allergy and their clinical correlations. Curr. Allergy Asthma Rep. 3 (2003) 345-351
11. Costagliola C., Prete A.D., Incorvaia C., Fusco R., Parmeggiani F., and Di Giovanni A. Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch. Clin. Exp. Ophthalmol. 239 (2001) 809-814
12. D'Arienzo P.A., Leonardi A., and Bensch G. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. Clin. Ther. 24 (2002) 409-416
13. EMEA. EPARs for authorised medicinal products for human use (2007). http://www.emea.europa.eu/htms/human/epar/a.htm
14. Fuchs T., Meinert A., Aberer W., Bahmer F.A., Peters K.P., Lischka G.G., Schulze-Dirks A., Enders F., and Frosch P.J. Benzalkonium chloride-a relevant contact allergen or irritant? Results of a multicenter study of the German Contact Allergy Group]. Hautarzt 44 (1993) 699-702
15. Ganz M., Koll E., Gausche J., Detjen P., and Orfan N. Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort. Adv. Ther. 20 (2003) 79-91
16. Goldschmidt P., and Luyckx J. Effects of lodoxamide (LOD), disodium cromoglycate (DSCG) and N-acetyl-aspartyl-glutamate sodium salt (NAAGA) on ocular active anaphylaxis. Allerg. Immunol. (Paris) 28 (1996) 124-126
17. Greiner J.V., and Udell I.J. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther. 27 (2005) 568-577
18. Groneberg D.A., Bielory L., Fischer A., Bonini S., and Wahn U. Animal models of allergic and inflammatory conjunctivitis. Allergy 58 (2003) 1101-1113
19. Herreras J.M., Pastor J.C., Calonge M., and Asensio V.M. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 99 (1992) 1082-1088
20. Hesselmar B., Aberg B., Eriksson B., and Aberg N. Allergic rhinoconjunctivitis, eczema, and sensitization in two areas with differing climates. Pediatr. Allergy Immunol. 12 (2001) 208-215
21. Horak F., Stubner P., Zieglmayer R., Kawina A., Moser M., and Lanz R. Onset and duration of action of ketotifen 0.025% and emedastine 0.05% in seasonal allergic conjunctivitis: efficacy after repeated pollen challenges in the Vienna Challenge Chamber. Clin. Drug Investig. 23 (2003) 329-337
22. Joseph Titi M. A critical look at ocular allergy drugs. Am. Fam. Physician 53 (1996) 2637-2642 2645-2646
23. Kamei C., Izushi K., and Tasaka K. Inhibitory effect of levocabastine on experimental allergic conjunctivitis in guinea pigs. J. Pharmacobiodyn. 14 (1991) 467-473
24. Khosravi E., Elena P.P., and Hariton C. Allergic conjunctivitis and uveitis models: reappraisal with some marketed drugs. Inflamm. Res. 44 (1995) 47-54
25. Leonardi A., and Abelson M.B. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin. Ther. 25 (2003) 2539-2552
26. Merayo-Lloves J., Zhao T.Z., Dutt J.E., and Foster C.S. A new murine model of allergic conjunctivitis and effectiveness of nedocromil sodium. J. Allergy Clin. Immunol. 97 (1996) 1129-1140
27. Netland P.A., Leahy C., and Krenzer K.L. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Am. J. Ophthalmol. 130 (2000) 717-723
28. Purello D'Ambrosio F., Gangemi S., Ricciardi L., Cuzzocrea S., and Di Lorenzo G. Lodoxamide versus spaglumic acid: a comparative double-blind trial on patients suffering from seasonal allergic conjunctivitis induced by Parietaria pollen. Allergol. Immunopathol. (Madr.) 25 (1997) 233-237
29. Schoch C. Effects of ketotifen 0.025% and lodoxamide 0.1% on eosinophil infiltration into the guinea pig conjunctiva in a model of allergic conjunctivitis. J. Ocul. Pharmacol. Ther. 19 (2003) 153-159
30. Schoch C. Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat. Ocul. Immunol. Inflamm. 13 (2005) 39-44
31. Secchi A., Ciprandi G., Leonardi A., Deschenes J., and Abelson M.B. Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis. Emadine Study Group. Acta Ophthalmol. Scand. 78 Suppl. 230 (2000) 42-47
32. Shoji J., Sakimoto T., Muromoto K., Inada N., Sawa M., and Ra C. Comparison of topical dexamethasone and topical FK506 treatment for the experimental allergic conjunctivitis model in BALB/c mice. Jpn. J. Ophthalmol. 49 (2005) 205-210
33. Spangler D.L., Bensch G., and Berdy G.J. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther. 23 (2001) 1272-1280
34. Vazquez Nava F., Salas Ramirez E., Mogica Mogica Jde D., and Beltran Guzman F.J. Prevalence and risk factors for allergic conjunctivitis in children. Comparative study in two communities]. Rev. Alerg. Mex. 49 (2002) 33-41
35. Yanni J.M., Stephens D.J., Parnell D.W., and Spellman J.M. Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J. Ocul. Pharmacol. 10 (1994) 665-675
36. Yanni J.M., Stephens D.J., Miller S.T., Weimer L.K., Graff G., Parnell D., Lang L.S., Spellman J.M., Brady M.T., and Gamache D.A. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J. Ocul. Pharmacol. Ther. 12 (1996) 389-400